Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Pancreatic Neoplasms: HELP
Articles by Frediano Inzani
Based on 10 articles published since 2010
(Why 10 articles?)
||||

Between 2010 and 2020, F. Inzani wrote the following 10 articles about Pancreatic Neoplasms.
 
+ Citations + Abstracts
1 Review The New World Health Organization Classification for Pancreatic Neuroendocrine Neoplasia. 2018

Inzani, Frediano / Petrone, Gianluigi / Rindi, Guido. ·Department of Anatomic Pathology, IRCCS Fondazione Policlinico Universitario A. Gemelli, Largo A. Gemelli, 8, Roma I-00168, Italy; Roma ENETS Center of Excellence, IRCCS Fondazione Policlinico Universitario A. Gemelli, Largo A. Gemelli, 8, Roma I-00168, Italy; Gynecological and Breast Pathology Unit, IRCCS Fondazione Policlinico Universitario A. Gemelli, Largo A. Gemelli, 8, Roma I-00168, Italy. · Department of Anatomic Pathology, IRCCS Fondazione Policlinico Universitario A. Gemelli, Largo A. Gemelli, 8, Roma I-00168, Italy; Roma ENETS Center of Excellence, IRCCS Fondazione Policlinico Universitario A. Gemelli, Largo A. Gemelli, 8, Roma I-00168, Italy; Anatomic Pathology Unit, IRCCS Fondazione Policlinico Universitario A. Gemelli, Largo A. Gemelli, 8, Roma I-00168, Italy. · Department of Anatomic Pathology, IRCCS Fondazione Policlinico Universitario A. Gemelli, Largo A. Gemelli, 8, Roma I-00168, Italy; Roma ENETS Center of Excellence, IRCCS Fondazione Policlinico Universitario A. Gemelli, Largo A. Gemelli, 8, Roma I-00168, Italy; Anatomic Pathology Unit, IRCCS Fondazione Policlinico Universitario A. Gemelli, Largo A. Gemelli, 8, Roma I-00168, Italy; Institute of Pathology, Università Cattolica-IRCCS Fondazione Policlinico Universitario A. Gemelli, Largo A. Gemelli, 8, Roma I-00168, Italy. Electronic address: guido.rindi@unicatt.it. ·Endocrinol Metab Clin North Am · Pubmed #30098710.

ABSTRACT: Based on the 2010 version, the 2017 World Health Organization (WHO 2017) classification is for pancreatic neuroendocrine neoplasms (PanNEN). The WHO 2017 classification introduces the novel well-differentiated neuroendocrine tumor of high grade (NET G3). A sharp distinction between NET and poorly differentiated neuroendocrine carcinoma (NEC) is emphasized to highlight substantial biological differences. Further changes comprise the definition of mixed neuroendocrine non-neuroendocrine neoplasm (MiNEN), to accommodate all grades of both neoplasm components, and the abolition of preneoplastic lesions given their rarity in the pancreas. The 2017 American Joint Cancer Committee classification (AJCC 2017) adopts such a classification for all digestive sites.

2 Article Competitive Testing of the WHO 2010 versus the WHO 2017 Grading of Pancreatic Neuroendocrine Neoplasms: Data from a Large International Cohort Study. 2018

Rindi, Guido / Klersy, Catherine / Albarello, Luca / Baudin, Eric / Bianchi, Antonio / Buchler, Markus W / Caplin, Martyn / Couvelard, Anne / Cros, Jérôme / de Herder, Wouter W / Delle Fave, Gianfranco / Doglioni, Claudio / Federspiel, Birgitte / Fischer, Lars / Fusai, Giuseppe / Gavazzi, Francesca / Hansen, Carsten P / Inzani, Frediano / Jann, Henning / Komminoth, Paul / Knigge, Ulrich P / Landoni, Luca / La Rosa, Stefano / Lawlor, Rita T / Luong, Tu V / Marinoni, Ilaria / Panzuto, F / Pape, Ulrich-Frank / Partelli, Stefano / Perren, Aurel / Rinzivillo, Maria / Rubini, Corrado / Ruszniewski, Philippe / Scarpa, Aldo / Schmitt, Anja / Schinzari, Giovanni / Scoazec, Jean-Yves / Sessa, Fausto / Solcia, Enrico / Spaggiari, Paola / Toumpanakis, Christos / Vanoli, Alessandro / Wiedenmann, Bertram / Zamboni, Giuseppe / Zandee, Wouter T / Zerbi, Alessandro / Falconi, Massimo. ·Institute of Pathology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma-Università Cattolica del Sacro Cuore, Roma ENETS Center of Excellence, Rome, Italyguido.rindi@unicatt.it. · Service of Biometry and Clinical Epidemiology, Research Department, and IRCCS Fondazione Policlinico San Matteo, Pavia, Italy. · Pathology Unit, San Raffaele Scientific Institute, Milan, Italy. · Department of Oncology, Cancer Campus, Villejuif, France. · Department of Endocrinology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma-Università Cattolica del Sacro Cuore, Roma ENETS Center of Excellence, Rome, Italy. · Department of Surgery, University Hospital Heidelberg, Neu Heidelberg, Germany. · Neuroendocrine Tumour Unit, Centre for Gastroenterology, London, United Kingdom. · Department of Pathology, Hopital Beaujon, Paris ENETS Center of Excellence, Clichy, France. · Section Endocrinology, Department of Internal Medicine, Erasmus University Medical Center and and Erasmus MC Cancer Institute Rotterdam, Rotterdam ENETS Center of Excellence, Rotterdam, The Netherlands. · Digestive and Liver Disease Unit, Sant'Andrea University Hospital, Roma ENETS Center of Excellence, Rome, Italy. · Department of Pathology, Rigshospitalet, Copenhagen University Hospital, Copenhagen ENETS Center of Excellence, Copenhagen, Denmark. · Department of Surgery, University College, Royal Free Hospital, London ENETS Center of Excellence, London, United Kingdom. · Pancreatic Surgery, Humanitas Clinical and Research Center, Humanitas Milan ENETS Center of Excellence, Milan, Italy. · Department of Surgery, Rigshospitalet, Copenhagen University Hospital, Copenhagen ENETS Center of Excellence, Copenhagen, Denmark. · Institute of Pathology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma-Università Cattolica del Sacro Cuore, Roma ENETS Center of Excellence, Rome, Italy. · Department of Hepatology and Gastroenterology, Charité, Campus Virchow Klinikum and Charite Mitte, University Medicine Berlin, Berlin ENETS Center of Excellence, Berlin, Germany. · Institute of Pathology, Stadtspital Triemli, Zurich, Switzerland. · Department of Surgery and Oncology, General and Pancreatic Surgery, The Pancreas Institute, Verona ENETS Center of Excellence, Verona, Italy. · Department of Pathology, Ospedale di Circolo, Università dell'Insubria, Varese, Italy. · Section of Pathology and ARC-Net Research Centre, Department of Diagnostics and Public Health, University and Hospital Trust of Verona, Verona ENETS Center of Excellence, Verona, Italy. · Department of Pathology, University College, Royal Free Hospital, London ENETS Center of Excellence, London, United Kingdom. · Institute of Pathology, University of Bern, Bern, Switzerland. · Pancreatic Surgery Unit, San Raffaele Scientific Institute, Milan, Italy. · Department of Pathology, Marche Polytechnic University, Ancona, Italy. · Department of Gastroenterology and Pancreatology, Hopital Beaujon, Paris ENETS Center of Excellence, Clichy, France. · Department of Medical Oncology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma-Università Cattolica del Sacro Cuore, Roma ENETS Center of Excellence, Rome, Italy. · Department of Medical Biology and Pathology, Cancer Campus, Villejuif, France. · Department of Molecular Medicine, University of Pavia, Pavia, Italy. · Pathology Department, Humanitas Clinical and Research Center, Humanitas Milan ENETS Center of Excellence, Milan, Italy. · Department of Pathology, Sacro Cuore-Don Calabria Hospital, Negrar, Italy. ·Neuroendocrinology · Pubmed #30300897.

ABSTRACT: BACKGROUND: The World Health Organization (WHO) and the American Joint Cancer Committee (AJCC) modified the grading of pancreatic neuroendocrine neoplasms from a three-tier (WHO-AJCC 2010) to a four-tier system by introducing the novel category of NET G3 (WHO-AJCC 2017). OBJECTIVES: This study aims at validating the WHO-AJCC 2017 and identifying the most effective grading system. METHOD: A total of 2,102 patients were enrolled; entry criteria were: (i) patient underwent surgery; (ii) at least 2 years of follow-up; (iii) observation time up to 2015. Data from 34 variables were collected; grading was assessed and compared for efficacy by statistical means including Kaplan-Meier method, Cox regression analysis, Harrell's C statistics, and Royston's explained variation in univariable and multivariable analyses. RESULTS: In descriptive analysis, the two grading systems demonstrated statistically significant differences for the major category sex but not for age groups. In Cox regression analysis, both grading systems showed statistically significant differences between grades for OS and EFS; however, no statistically significant difference was observed between the two G3 classes of WHO-AJCC 2017. In multivariable analysis for the two models fitted to compare efficacy, the two grading systems performed equally well with substantially similar optimal discrimination and well-explained variation for both OS and EFS. The WHO-AJCC 2017 grading system retained statistically significant difference between the two G3 classes for OS but not for EFS. CONCLUSIONS: The WHO-AJCC 2017 grading system is at least equally performing as the WHO-AJCC 2010 but allows the successful identification of the most aggressive PanNET subgroup. Grading is confirmed as probably the most powerful tool for predicting patient survival.

3 Article Pancreatic neuroendocrine tumors in MEN1 disease: a mono-centric longitudinal and prognostic study. 2018

Chiloiro, S / Lanza, F / Bianchi, A / Schinzari, G / Brizi, M G / Giampietro, A / Rufini, V / Inzani, F / Giordano, A / Rindi, G / Pontecorvi, A / De Marinis, L. ·Department of Endocrinology, Catholic University of the Sacred Heart, Rome, Italy. · Department of Radiology, Catholic University of the Sacred Heart, Rome, Italy. · Department of Oncology, Catholic University of the Sacred Heart, Rome, Italy. · Department of Nuclear Medicine, Catholic University of the Sacred Heart, Rome, Italy. · Department of Anatomic Pathology, Catholic University of the Sacred Heart, Rome, Italy. · Department of Endocrinology, Catholic University of the Sacred Heart, Rome, Italy. laurademarinis@yahoo.it. ·Endocrine · Pubmed #28567607.

ABSTRACT: PURPOSE: Multiple endocrine neoplasia type 1 (MEN1) is an inherited endocrine neoplastic syndrome associated with a greater risk of endocrine tumor development like pancreatic neuroendocrine tumors (p-NET), with different clinical characteristics from sporadic ones. This paper aims to compare clinical, hystological and morphological aspects of p-NET in patients affected from MEN1 (MEN1+) and not-affected ones (MEN1-). METHODS: We performed a retrospective observational study. Data was collected between December 2010 and December 2015, including patients with a histological diagnosis of p-NET and radiological imaging. We compared clinical, histological, radiological, and prognostic aspects of MEN+ p-NET with MEN-1 p-NET. RESULTS: Of the 45 patients enrolled, 13 MEN1+ and 21 MEN1- cases were analyzed. Frequency of not secreting p-NETs and insulin secreting p-NETs, histopathological grades and Ki67 expression were superimposable between MEN1+ and MEN1- patients. MEN1+ pNETs are more often multicentric compared to MEN1- pNETs. Frequency of liver and nodes metastatic spread was higher in MEN1- p-NET compared to MEN1+ p-NET. Analyzing p-NET according to the disease outcome, we found that recovered and stable p-NETs in MEN1+ patients, compared to MEN1- cases, are diagnosed at lower age (p = 0.04/p = 0.002) and that are more frequently multifocal lesions (p = 0.009/p = 0.002). CONCLUSIONS: In our study pNETs in MEN1+ and pNETs in MEN1- don't significantly differ for prognosis but only for clinical features. p-NET stage disease and prognosis can be positively influenced by early diagnosis and screening in index patients' first-degree relatives.

4 Article RUNX3 as a Potential Predictor of Metastasis in Human Pancreatic Cancer. 2017

Rossi, Ernesto / Bagalà, Cinzia / Inzani, Frediano / Leoncini, Emanuele / Brunelli, Chiara / Lanza, Paola / Basso, Michele / Mattiucci, Gian Carlo / Cassano, Alessandra / Rindi, Guido / Barone, Carlo / Schinzari, Giovanni. ·Department of Medical Oncology, Fondazione Policlinico "A.Gemelli", Largo A. Gemelli, Rome, Italy ernestorossi.rm@gmail.com. · Department of Medical Oncology, Fondazione Policlinico "A.Gemelli", Largo A. Gemelli, Rome, Italy. · Institute of Anatomic Pathology, Fondazione Policlinico "A.Gemelli", Largo A. Gemelli, Rome, Italy. · Section of Hygiene, Institute of Public Health, Fondazione Policlinico "A.Gemelli", Largo A. Gemelli, Rome, Italy. · Department of Radiation Oncology, Fondazione Policlinico "A.Gemelli", Largo A. Gemelli, Rome, Italy. ·In Vivo · Pubmed #28882948.

ABSTRACT: BACKGROUND/AIM: In genetically engineered murine models of pancreatic ductal adenocarcinomas (PDAC), high levels of Runx3 increase the metastatic potential of cancer cells. In this study we evaluated the role of Runx3 in human pancreatic cancer. MATERIALS AND METHODS: Runx3 was retrospectively assessed by immunohistochemistry in seventy-eight tumor samples of patients who underwent surgical resection for PDCA and were followed at least for 24 months. RESULTS: Thirty-two cases resulted completely negative for Runx3; forty-six showed highly variable expression. We established an optimal cut-off value of Runx3 in predicting distant metastasis equal to 0.04. The odds ratio (ORs) for development of distant metastases at multivariate analysis for patients having Runx3 ≥0.04 was 4.26 (p=0.043) and 4.68 (p=0.032) after adjusting for residual tumor and treatment, respectively; OR for development of metastases in multiple sites was 4.28 (p=0.025) for Runx3 ≥0.04. CONCLUSION: Our results support the ability of Runx3 to contribute to the dissemination of human PDAC thus confirming the observations from murine models.

5 Article The Accessory Spleen Is an Important Pitfall of 68Ga-DOTANOC PET/CT in the Workup for Pancreatic Neuroendocrine Neoplasm. 2017

Rufini, Vittoria / Inzani, Frediano / Stefanelli, Antonella / Castaldi, Paola / Perotti, Germano / Cinquino, Annarita / Indovina, Luca / Rindi, Guido. ·From the *Institute of Nuclear Medicine, †Roma ENETS Center of Excellence for the Diagnosis and Cure of Neuroendocrine Tumors, ‡Institute of Pathology, and §Division of Medical Physics, Università Cattolica del Sacro Cuore-Fondazione Policlinico A. Gemelli, Rome, Italy. ·Pancreas · Pubmed #27846139.

ABSTRACT: OBJECTIVE: The aim of the study was to assess the value and potential pitfalls of Ga-DOTANOC positron emission tomography/computed tomography (PET/CT) in patients with suspected pancreatic neuroendocrine neoplasms (pNEN). METHODS: Consecutive patients referred for Ga-DOTANOC PET/CT for suspected pNEN between May 1, 2011, and October 31, 2014, were retrospectively assessed. Scan data were compared with cytological/histological final diagnosis. Pancreatic neuroendocrine neoplasm detection rate was determined on per-patient and per-lesion basis. Maximum standardized uptake values of lesions were determined. RESULTS: Fifty-eight patients with 65 lesions were enrolled. Twelve patients had nonconfirmed diagnosis; of these, 7 were positive and 5 negative at PET/CT. Of 46 patients with confirmed diagnosis, 36 had pNEN; of these, 33 were positive, 1 negative, and 2 nonevaluable at PET/CT. Ten patients had non-NE lesions, of which 8 were positive, 1 negative, and 1 nonevaluable at PET/CT. Of 48 patients with positive PET/CT, 8 proved to have non-NE lesions, of which 6 were intrapancreatic accessory spleen. No significant maximum standardized uptake values difference was found between pNEN and non-NE lesions. CONCLUSIONS: Intrapancreatic accessory spleen is an important pitfall in Ga-DOTANOC PET/CT for suspected pNEN. Cytological/histological confirmation is mandatory before any surgical procedure is undertaken.

6 Article Accuracy and inter-observer agreement of the Procore™ 25 gauge needle for endoscopic ultrasound-guided tissue core biopsy. 2015

Attili, Fabia / Petrone, Gianluigi / Abdulkader, Ihab / Correale, Loredana / Inzani, Frediano / Iglesias-Garcia, Julio / Hassan, Cesare / Andrade Zurita, Santiago / Rindi, Guido / Dominguez-Muñoz, J Enrique / Costamagna, Guido / Larghi, Alberto. ·Digestive Endoscopy Unit, Catholic University, Rome, Italy. · Department of Pathology, Catholic University, Rome, Italy. · Department of Pathology, University Hospital of Santiago de Compostela, Spain. · Gastroenterology Department, Foundation for Research in Digestive Diseases (FIENAD), University Hospital of Santiago de Compostela, Spain. · Digestive Endoscopy Unit, Catholic University, Rome, Italy. Electronic address: alberto.larghi@yahoo.it. ·Dig Liver Dis · Pubmed #26216067.

ABSTRACT: BACKGROUND: Scanty data on the performance of the new 25-gauge Procore™ biopsy needle are available. METHODS: Consecutive patients who underwent endoscopic ultrasound-guided fine needle biopsy (EUS-FNB) using the 25G Procore™ were retrospectively retrieved. All samples were independently reviewed by 3 pathologists for the following: histological, cytological or no specimen, neoplasia, diagnostic or non-diagnostic. Diagnostic accuracy and inter-rater concordance among pathologists were calculated. RESULTS: 94 patients underwent EUS-FNB of 101 sites (69 solid masses, 25 lymph nodes, 5 wall thickening). Forty-one biopsies (40.5%) were classified as histological samples by at least two pathologists, 29 as cytological (28.7%), 31 had no sample (30.7%). Good and almost perfect agreements among pathologists in defining cytological vs. histological samples (k 0.82; 95% CI: 0.74-0.90), diagnostic vs. non-diagnostic (k 0.95; 95% CI: 0.85-1.00) and neoplastic vs. non-neoplastic (k 0.94; 95% CI: 0.83-1.00). According to consensus rating, 61 cases were diagnostic samples (60.4%). Histological samples were more likely to lead to a correct diagnosis (OR, 4.1; 95% P=0.027), while neoplastic lesions were less likely to be correctly classified than benign (OR, 0.11; P=0.04). CONCLUSIONS: EUS-FNB with the Procore™ 25G needle provided samples for histological examination in only 40% of the cases, with 31% of inadequate specimens, despite excellent results in term of inter-observer variability.

7 Article An unusual cause of pancreatic mass lesion. 2013

Panic, Nikola / Inzani, Frediano / Larghi, Alberto. ·Digestive Endoscopy Unit, Catholic University, Rome, Italy. ·Gastroenterology · Pubmed #23499286.

ABSTRACT: -- No abstract --

8 Article A case of insulinoma detected by (68)Ga-DOTANOC PET/CT and missed by (18)F-dihydroxyphenylalanine PET/CT. 2013

Treglia, Giorgio / Inzani, Frediano / Campanini, Nicoletta / Rindi, Guido / Agnes, Salvatore / Giordano, Alessandro / Rufini, Vittoria. ·Institute of Nuclear Medicine, Department of Bioimaging and Radiological Sciences, Catholic University of the Sacred Heart, Rome, Italy. giorgiomednuc@libero.it ·Clin Nucl Med · Pubmed #23377414.

ABSTRACT: A 65-year-old woman with suspected insulinoma on the basis of clinical, biochemical, and conventional imaging data underwent F-dihydroxyphenylalanine (DOPA) PET/CT and Ga-DOTANOC PET/CT. F-DOPA PET/CT did not show any focal uptake in the pancreas, whereas Ga-DOTANOC PET/CT showed a focal area of intense uptake in the pancreatic tail. The patient underwent surgery and an insulinoma of about 20 mm in diameter was detected in the pancreatic tail. F-DOPA PET may fail in localizing insulin secreting tumors in adults; in these cases, the use of Ga-somatostatin analogs may lead to the correct diagnosis.

9 Minor Is 18F-Fluorodeoxyglucose the Tracer of Choice for Functional Imaging of Neuroendocrine Tumors Grade 3? A Case Report. 2018

Lorusso, Margherita / Inzani, Frediano / Castaldi, Paola / Menghi, Roberta / Schinzari, Giovanni / Rindi, Guido / Rufini, Vittoria. ·Institute of Nuclear Medicine Università Cattolica del Sacro Cuore-Fondazione Policlinico A. Gemelli Rome ENETS Center of Excellence for the Diagnosis and Cure of Neuroendocrine Tumors Rome, Italy Institute of Pathology Università Cattolica del Sacro Cuore-Fondazione Policlinico A. Gemelli Rome ENETS Center of Excellence for the Diagnosis and Cure of Neuroendocrine Tumors Rome, Italy Nuclear Medicine, Department of Radiology and Clinical Radiotherapy Policlinico SS Annunziata Chieti, Italy Institute of Nuclear Medicine Università Cattolica del Sacro Cuore-Fondazione Policlinico A. Gemelli Rome ENETS Center of Excellence for the Diagnosis and Cure of Neuroendocrine Tumors Rome, Italy Department of Digestive Surgery Università Cattolica del Sacro Cuore-Fondazione Policlinico A. Gemelli Rome ENETS Center of Excellence for the Diagnosis and Cure of Neuroendocrine Tumors Rome, Italy Department of Medical Oncology Università Cattolica del Sacro Cuore-Fondazione Policlinico A. Gemelli Rome ENETS Center of Excellence for the Diagnosis and Cure of Neuroendocrine Tumors Rome, Italy Institute of Pathology Università Cattolica del Sacro Cuore-Fondazione Policlinico A. Gemelli Rome ENETS Center of Excellence for the Diagnosis and Cure of Neuroendocrine Tumors Rome, Italy Institute of Nuclear Medicine Università Cattolica del Sacro Cuore-Fondazione Policlinico A. Gemelli Rome ENETS Center of Excellence for the Diagnosis and Cure of Neuroendocrine Tumors Rome, Italy vittoria.rufini@unicatt.it. ·Pancreas · Pubmed #29521949.

ABSTRACT: -- No abstract --

10 Minor Masking effect of chronic pancreatitis in the interpretation of somatostatin receptor positron emission tomography in pancreatic neuroendocrine tumors. 2013

Treglia, Giorgio / Farchione, Alessandra / Stefanelli, Antonella / Brizi, Maria Gabriella / Larghi, Alberto / Inzani, Frediano / Rindi, Guido / Rufini, Vittoria. · ·Pancreas · Pubmed #23591437.

ABSTRACT: -- No abstract --